| DC47657 |
LT-850-166
|
LT-850-166 is a potent FLT3 inhibitor with the capacity of overcoming a variety of FLT3 mutations. |
| DC46932 |
Luxeptinib
|
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. |
| DC44089 |
FLT3-IN-4
|
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia. |
| DC28136 |
Tandutinib hydrochloride
|
Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier. |
| DC11780 |
FLT3-IN-5e
|
FLT3-IN-5e is a nove potent, selective FLT3 inhibitor with Kd of 3.6 nM, IC50 of <6 nM. |
| DC10922 |
AAE871
|
AAE871 (AAE-871) is a potent type I kinase inhibitor of FLT3 with IC50 of 34 nM, potently inhibits proliferation of FLT3-ITD- and D835Y-expressing cells (IC50<10 nM) through selective inhibition of FLT3 kinase activity.. |
